A 913-person economic evaluation of the PReDicT antidepressant algorithm found nearly identical EQ-5D quality-of-life gains vs. treatment as usual (+0.139 vs. +0.140) and nearly identical societal cost reductions (−€2,589 vs. −€2,602), while cost-effectiveness probabilities were only 46% to 59% at trial level but exceeded 80% in the UK.1 The algorithm signal was country-specific and capability-weighted, …
A 2026 medRxiv preprint interviewed 15 health-system stakeholders about CARES, a freestanding addiction-risk screening platform, and found a clear implementation split: people wanted better substance-use prevention tools than current clinic screening, but provider burden, stigma, knowledge gaps, and medical-record liability could block uptake.1 Research Highlights Stakeholders saw a screening gap: all 15 interviewees held leadership …
Brief screening tools for early dementia risk are essential in primary care. A 2026 study by You et al. evaluated the AD8 informant questionnaire in older Chinese-speaking adults in Australia, mapping how cognitive, functional, social, and language-barrier risks stack before dementia is formally diagnosed.1 Research Highlights The AD8 dementia screening interview is an 8-item informant-based …